Immuron Ltd — Investor Presentation 2008

Jun 25, 2008

==> picture [205 x 57] intentionally omitted <==

Anadis Presentation at International BIO conference in San Diego

Thursday 26 June 2008

Dr. Oren Fuerst, VP Business Development at Anadis has presented at the Investor Business forum of International Bio, the largest annual biotechnology conference, held this year at San Diego, California. Anadis was selected from a range of biotech companies, to present on June 19th at The international conference attended by more than 20,000 investors, scientists and executives from around the world. Following is the presentation made.

For further information contact:

Dr. Oren Fuerst‐ VP, Business Development Email: oren@anadis.com Tel +1 646 536 9289

Arie Nudel‐ Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Disclaimer for Presentation

This presentation contains forward‐looking statements regarding the therapeutic and commercial potential of Anadis technologies which are subject to risks and uncertainties. Any statement describing the company’s goals, expectations, intentions or beliefs is a forward‐looking statement and should be considered an “at‐risk” statement. Such statements involve known and unknown risks that may cause the actual results, performance or achievements to vary from the statements in this presentation.

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

Presented by
Dr. Oren VP Business
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

1

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
D eve op ng an i commerc a i z ng ra i O y e D vere
Passive and Active Immunity products Derived
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

specific antigens
•
antibodies and
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

other proteins (Nutraceutical/ Medical Food)
•
Established clinical record and GRAS status can be
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

applied across multiple markets
•
Publicl traded on ASX
y
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Seeking partners for our commercial and
develo ment sta e roducts
p g p
----- End of picture text -----

2

==> picture [721 x 68] intentionally omitted <==

Safety Efficacy/Safety

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

EVProtec (EV‐71)
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

IMMDIF (c.Diff)
MucoGard (Mucositis)
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

BioGard (HIV adjunct)
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

ro t ec t yn
FluGard (influenza)
----- End of picture text -----

3

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

,
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
to
Indication specific bovine (cows) vaccines
achieve hi h titers of antibodies and other
g
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

proteins in the colostrum
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

high antibodies and protein levels
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Protein Shielding technology to allow oral
in the
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

intestinal tract
----- End of picture text -----

4

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
GRAS (Generally Recognized As Safe) ‐ product
or exci ient
p
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Natural product with Oral delivery
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
R ap id eve opment cyc e new stra ns d l l ( i )
•
Passive and Active Immunit ( throu h
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

Immuron: a JV with Hadassah)
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
ca a e a ry manu ac t ur ng
----- End of picture text -----

5

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Lab and animal work at research institutions
•
Most launched
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

supplements or Medical Foods
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Hi g hl y sca a l bl e manu actur ng us ng f i i BSE ree F
Australian dairy farms and processors
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Partnerships with pharmas, academic
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

6

==> picture [721 x 68] intentionally omitted <==

• M ar k e t aunc l h

• Recognized Dairy leader

• Complimentary Medicine

• Pharma and Nutritional Distribution Partners

• Medical Food or Nutritional Supplement

• Regional and National Partners incl govt

• Rapid consumer marketing

• Food or nutritional supplement

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Dr. Zeil Rosenberg, CEO
–
Becton Dickinson ( BD ), U.S. AID
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Dr. Oren Fuerst, VP Business Development
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

–
KPMG F l C l bi a a e us. c & Y l B S h .
, acu ty o um
•
Dr. Grant Rawlin, Head of R&D
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

8

Scientific Advisory Board

• Professor Roy Robbins Brown (Infectious Diseases)

• Head of the Department of Microbiology and Immunology, University of Melbourne

• Professor Colin Cha p man

• Former Dean of Pharmacy, Monash University

• Professor Andrew Sinclair (Nutrition)

• Chair , Human Nutrition , School of Exercise & Nutrition Sciences , Deakin University,

• Professor Frank Dudley (Clinical GI)

• Former Chair, Gastroenterology, Alfred Hospital, Melbourne.

• Professor David Anderson (GI Microbiology)

• De p ut y Director , Macfarlane Burnett Institute for Medical Research & Public Health

• Professor Lorena Brown (Influenza) – Department of Microbiology & Immunology ‐ University of Melbourne

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Launch Travelan (Traveler’s Diarrhea; anti‐E.
coli ) in the U.S.
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Initiate an additional clinical trial on C.Diff
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
I n t ate c i i li n ca tr a on ancer x re ate i l i l C R l d
Mucositis
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Partnership agreements for C. difficile and
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

10

Illustration I: High concentration of anti-LPS . and other antibodies against E coli (used in Anadis gastro indications) help reduce GI inflammatory sequella

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Scanning electron photomicrograph showing
Enterotoxigenic E coli (ETEC) adhering to colon
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

carcinoma cell line in absence of Travelan antibodies
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

Enterotoxigenic E coli (ETEC) in presence of Travelan antibodies. Bacteria agglutinated (blocked) and relatively fewer on surface

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

I ll ustration 2: F u l b o d y
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Novel oral/ respiratory spray to deliver colostrum derived
antibodies
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

•
Immediate protection from airborne infectious virus,
including post ‐exposure prophylaxis (PEP)
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Numerous animal studies already conducted
•
Stand alone product and/or combined with existing
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

products
•
Core technology provides unique advantages
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

–
Affordable, Polyclonal antibody approach
–
6 months cycle for Abs to new flu strains, including lethal
----- End of picture text -----

ones (e.g. Avian flu)

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 69] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
D eve op ng an i commerc a i z ng ora i y e vere
Passive and Active Immunity products Derived
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

specific antigens
•
Broad market
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

–
Commercial: E.coli, Rotavirus, EV71
–
Develo ment: Clostridia Difficile Mucositis HIV ad j .
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

----- Start of picture text -----

therapy, IBD, Flu
•
Naturally occurring antibodies and other proteins
----- End of picture text -----

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

•
Established clinical record and GRAS status can be
applied across multiple markets
----- End of picture text -----

13